NCT03038711View on ClinicalTrials.gov

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

August 10, 2017

Study Completion Date

August 10, 2017

Conditions
Ulcerative Colitis
Interventions
DRUG

BMS-986166

Specified dose on specified days

OTHER

Placebo matching BMS-986166

Specified dose on specified days

Trial Locations (1)

78744

PPD Development, LLC, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY